乌鸦传媒

<乌鸦传媒 class='mpt-top_cat_title'>Cardiology >

Venous Thrombosis

News, opinions and meeting coverage in cardiology.

ASH over a photo of Orange County Convention Center, Orlando, FL

<乌鸦传媒>Study Bolsters Case for Novel Xarelto Formulation for Kids

Pharmacokinetic data indicate appropriate dosing schemes across wide range of weight categories

A bottle of Xarelto over a computer rendering of a blood clot

<乌鸦传媒>DOAC Disappoints in Thrombotic Autoimmune Disorder

Drug may, in fact, pose serious risks in this population

<乌鸦传媒>Enoxaparin May Be Underdosed for CRC Surgery Patients

Standard dose yielded low anticoagulation levels in 68% but no increase in venous thromboembolism

<乌鸦传媒>Doing Shoulder Surgery in Denver (or La Paz)? Read This

40-fold (!) increase in 30-day pulmonary embolism risk with procedures performed at high altitude

<乌鸦传媒>Visual Guide to AVERT's VTE Prevention in Cancer

Apixaban effective against important chemotherapy side effect

<乌鸦传媒>Cancer-VTE Trial Falls Short

High dropout rate undermines rivaroxaban prophylaxis trial

<乌鸦传媒>LMWH Prevails for VTE Prevention in Guideline

ASH unveils first six chapters of comprehensive recommendations

<乌鸦传媒>ESC: Rivaroxaban Doesn't Prevent VTE after Acute Illness

Efficacy shown in prior trial is lost, but safety gained in this setting

<乌鸦传媒>Post-Op VTE Risk Up After Intra-Op Blood Transfusion

Deep vein thrombosis, pulmonary embolism more common within 30 days

<乌鸦传媒>Study: Hospitals Overuse VTE Prophylaxis

65% of patients in non-ICU wards in Michigan got more than recommended

<乌鸦传媒>Thrombectomy Takes Away Need for Lytics in PE

Favorable results with FlowTriever system in FLARE study

<乌鸦传媒>Novel Drug Reverses Anticoagulation in Emergencies

Andexanet stops 90% of action of factor Xa inhibitors

<乌鸦传媒>AHA: Brief NOAC Interruption Safer Than Warfarin in Afib Ablation

Fewer major bleeds than with uninterrupted warfarin in Japanese trial

<乌鸦传媒>ACC: Even Very Low Dose Rivaroxaban Prevents Recurrent VTE

Results from EINSTEIN CHOICE point to new clinical pathway

<乌鸦传媒>2010: When IVC Filter Use Started Going Down

FDA warning apparently made impact

<乌鸦传媒>After Brain Bleed, Anticoagulant Restart May Help Regardless of Subtype

Lobar and nonlobar cases both had better outcomes in meta-analysis

<乌鸦传媒>Um, Excuse Me, Why Did You Stop My Post-Op Anticoagulant?

Cardiology writer learns firsthand about real-world practice

<乌鸦传媒>AHA: Study Finds Celebrex Safe for Heart

But naproxen not as heart safe as believed

<乌鸦传媒>ESC: NOAC Reversal Agent Effective in Study

But results may not sway FDA

<乌鸦传媒>Compression Stockings; Stroke Prevention; Stents and Meds

Cardiovascular Daily wraps up the top cardiology news of the week

<乌鸦传媒>Aspirin Before Cardiac Surgery: Not Harmful, But Not Helpful

Death, thrombotic complication, and bleeding risk all unaffected in ATACAS trial

<乌鸦传媒>Patient Registries See Promise and Challenges Ahead

Physician-driven registries adapt to a changing health system

<乌鸦传媒>CardioBrief: Dollars for Heart Docs

Analysis of CMS database shows some docs pocketed millions from drug and device makers.

<乌鸦传媒>CardioBreak: Modern Bloodletting, a New Statin Strategy

Recent developments of interest in cardiovascular medicine.

<乌鸦传媒>Missed Doses Cripple Postop DVT Prevention

Missed doses of prophylactic anticoagulation account for much of the deep vein thrombosis that occurs in surgery and trauma patients, a study showed.

<乌鸦传媒>Xarelto Gets a No for Stent Thrombosis

SILVER SPRING, Md. -- The FDA has rejected an application for a new indication allowing rivaroxaban (Xarelto) to be used to reduce the risk of stent thrombosis in patients with acute coronary syndrome.

<乌鸦传媒>Extended Apixaban Stops VTE Recurrence

ATLANTA -- Apixaban taken for an additional year after standard venous thromboembolism (VTE) treatment reduced recurrent events in a placebo-controlled trial, researchers said.

<乌鸦传媒>Fainting in PE Signals High Risk

ATLANTA -- Patients with pulmonary embolism brought to emergency rooms because they had passed out tended to have the most ominous risk factors for poor outcomes, a researcher said here.

<乌鸦传媒>FDA Warns of Clot Risk with Yaz, Other OCs

Labels for oral contraceptives that contain drospirenone will now note that studies have shown up to a threefold increased risk of blood clots compared with other birth control pills.

<乌鸦传媒>Cardiologist Who Revealed Echo Errors Out of a Job

MILWAUKEE -- A cardiologist whose research at a national medical meeting revealed that other doctors at her hospital were misreading a substantial number of diagnostic echocardiograms has been fired by that hospital, the Journal Sentinel and 乌鸦传媒 have learned.

<乌鸦传媒>In Pregnancy, DVT Mostly Occurs in Left Leg

Pregnant women are more likely to have deep vein thrombosis in their left leg, researchers have found.

<乌鸦传媒>Hidden Dangers of Herbal Meds Reviewed

Herbal medicines are not always the harmless nostrums that many patients and even some physicians think, but may actually contribute to cardiovascular morbidity and mortality, researchers warned.

<乌鸦传媒>AHA: FDA Drops Clopidogrel Bomb at AHA

ORLANDO -- The FDA has issued a public health advisory warning patients and physicians that concommitant use of clopidogrel (Plavix) and omeprazole (Prilosec and Prilosec OTC) blunts the antiplatelet effect of clopidogrel, so the combination should be avoided.

<乌鸦传媒>NBC's Tim Russert Dead at Age 58

WASHINGTON -- Tim Russert, 58, host of NBC's "Meet the Press" and the network's Washington bureau chief, collapsed and died at his office today.